More Stories

Informist, Saturday, Feb. 1, 2025

MUMBAI – Quarterly earnings of major pharmaceutical companies are likely to take centre stage next week, thereby lending key triggers to the direction of stocks in the sector. Investor focus will remain on corporate earnings to gauge how major companies fared amid sectoral headwinds such as a moderation in sales in key markets, such as the US, and lack of significant product launches, analysts said.

The week will start off with Nifty Next 50-constituent Divi's Laboratories Ltd.'s earnings for the December quarter on Monday. The drugmaker is likely to report strong on-year growth in earnings for Oct-Dec, on the back of robust growth across business segments, especially the high-margin custom synthesis vertical, according to analysts. However, the company is expected to see a sequential decline in its financial metrics, they said.

Alembic Pharmaceuticals Ltd., Gland Pharma Ltd., Eris Lifesciences Ltd., J.B. Chemicals & Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Abbott India Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd., and Caplin Point Laboratories Ltd. are the other pharma majors that will post their earnings for the December quarter next week.

Some pharmaceutical stocks could rise after the government proposed exemptions on customs duty for some drugs, which could benefit the drug manufacturers. Finance Minister Nirmala Sitharaman on Saturday, while presenting the Union Budget for 2025-26 (Apr-Mar), proposed to exempt customs duty on 36 additional life-saving drugs. She also said the government would apply full exemption and concessional duty on some bulk drugs.

The Nifty Pharma index was the second-biggest laggard among sectoral indices this week as it fell 2.5%. Most stocks in the index ended lower for the week, with shares of Aurobindo Pharma, Natco Pharma Ltd., and Ipca Laboratories Ltd. falling around 6% and becoming the worst hit. Cipla and
Zydus Lifesciences gained a modest 2% this week.

TOP HEADLINES

* Earnings Outlook: Custom synthesis ops likely to boost Divi's profit, margin

* Earnings Review: Sun Pharma Oct-Dec PAT growth led by India ops

* Analyst Concall: Sun Pharma cuts FY25 R&D guidance to 7% of sales

* Earnings Review: Cipla's results beat Street view; PAT jumps 49% on year

* Analyst Concall: Cipla to ramp up Lanreotide supply in US from Mar
* Cipla expects to exceed EBITDA margin guidance for FY25

* Analyst Concall: Biocon says getting ready to launch GLP-1 pdts globally
* Earnings Review: Biocon's top line falls for first time since Apr-Jun 2017
* Aurobindo Pharma gets positive opinion for Dyrupeg from European drug panel
* Pfizer Oct-Dec PAT falls 1.8% on year, sales down 0.4%

* Jyothy Labs Oct-Dec consol PAT falls nearly 4% YoY to INR 874 million
* Jubilant Pharmova Oct-Dec consolidated PAT rises 51% YoY to INR 1.01 bln

* Jubilant Pharmova arm makes voluntary prepayment of $25-mln term loan
* Piramal Pharma extends deadline to sell decommissioned unit indefinitely
* Piramal Pharma Oct-Dec consol PAT falls nearly 64% YoY to INR 36.8 million
* Ajanta Pharma Oct-Dec consol PAT rises 10.9% YoY to INR 2.33 billion

* Natco Pharma gets US FDA approval for everolimus tablets
* Granules India arm gets US FDA OK for Lisdexamfetamine Dimesylate capsules

* Granules India's Oct-Dec consol PAT falls 6.4% on year, sales fall 1.5%
* Granules India's Andhra unit gets EU good manufacturing practice certificate
* Jubilant Pharmova Singapore arm acquires 80% stake in France-based Jasmin
* Aurobindo Pharma arm's Telangana unit gets 'voluntary action indicated' tag
* Biocon board OKs issuance of CPs of INR 5.70 bln on private placement basis
* Analyst Concall: Torrent Pharma seeks to be cash positive by H1 FY27
* Earnings Review: Torrent Pharma Oct-Dec consol PAT growth lowest in 6 qtrs
* Laurus Labs Oct-Dec consol net profit surges fourfold YoY to INR 923 mln
* Analyst Concall:PAT fell on Bharat Serums acquisition costs - Mankind Pharma
* BUDGET: Govt to set up daycare cancer centres in all govt hospitals in 3 yrs

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by Alina Geogy

Edited by Tanima Banerjee

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.